SUSTAINED RELEASE FORMULATION USING A GASTRIC RETENTION DRUG DELIVERY SYSTEM, CAPABLE OF CONTROLLING THE SWELLING DEGREE OF POLYMER

摘要

PURPOSE: A sustained release formulation using a gastric retention drug delivery system is provided to enable drugs to stay in the gastrointestinal tract for a long time and release the drugs continuously by adding a first controlled-release base and a second controlled-release base besides a swelling polymer.;CONSTITUTION: A sustained release formulation using a gastric retention drug delivery system comprises: a pharmacological activity component, a swelling polymer, a first controlled-release base, and a second controlled-release base. The first controlled-release base is dissolved under an acidic condition. The second controlled-release base is dissolved under a weak acidic or a basic condition. 10-20wt% of the first controlled-release base is included to the swelling polymer. 10-40wt% of the second controlled-release base is included to the swelling polymer. The pharmacological acitivity component is selected from a group comprising pregabalin, gabapentine, metformin, ciprofloxacin, levodopa, trazodone, rebamipide, itopride, mosapride, teprenone, simvastatin, atorvastatin, pravastatin, pitavastatin, valsartan, losartan, candesartan, olmesartan, and azilsartan.;COPYRIGHT KIPO 2013;[Reference numerals] (AA) Elution rate(%); (BB) Lyrica capsule 150mg; (CC) Example 2; (DD) Testing solution collecting time(minutes)